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Abstract
Molecular and biochemical expressions of matrix
metalloproteinases in breast cancer tissue and cells
offers promise in helping us understand the breast
cancer microenvironment, and also in the future it is
hoped this will improve its detection, treatment and
prognosis. In a retrospective study recently published
in BMC Cancer, microenvironment predisposing to
breast cancer progression, metastatic behavior and
the expression of matrix metalloproteinase-1 (MMP-1)
and its correlation with well-known biochemical,
molecular and clinicopathologic factors in breast
cancer cells and cancer-associated stromal cells was
examined; this study also analyzed patient survival in
different breast cancer subtypes. The positive
correlation in breast tumor and stromal cells between
MMP-1 expression and several markers of tumor
grade and stage provide us with some useful new
insights into important questions about the molecular
profiling of the stromal microenvironment in
metastatic breast cancer. The study showed that
MMP-1 expression is strongly associated with poor
clinical outcome, so now we look forward to future
larger studies in breast cancer patients in which we
can relate wider MMP molecular profiling to identify
lethal tumor and stromal microenvironments
predisposing to breast cancer progression, metastatic
behavior and poor prognosis.
Please see related article http://www.biomedcentral.
com/1471-2407/11/348
Introduction
Breast cancer (BC) is the most common cancer in
women worldwide, comprising at least 16% of all female
cancers. BC results from multiple environmental and
hereditary risk factors, even though genetic traits, age
and hormones are the main recognized BC-predisposing
risk factors [1]. Human female BC encompasses a vari-
ety of tumors, which differ in their morphological, bio-
chemical and molecular characteristics, all guiding
clinical outcome and patient survival. Although well-
documented classic diagnostic/prognostic biomarkers/
profiles are reliable (for example, tumor grade and stage,
p53, bcl-2, Ki-67, hormone receptor status,: human epi-
dermal growth factor receptor 2 (HER-2) expression),
there is the urgent need to differentiate between BC
subclasses (for example, non-basal-like luminal A and B,
basal-like, triple-negative BC)[2,3], patients with differ-
ent prognoses and treatment responses to the same
therapy [4-6].
Examining new BC biomarkers has proven that
matrix metalloproteinases (MMP), which are zinc-
dependent endopeptidases belonging to the Metzincin
superfamily, are involved in several key events of both
physiologic processes (for example, tissue remodelling,
stem cell differentiation and proliferation, apoptosis)
[7-11] and in pathological conditions (for example,
inflammation, degeneration and cancer) [12-14]. The
MMP family comprises several classes of proteases
[15], which cleave almost all extracellular matrix com-
ponents and a variety of proteins and growth factors
crucial for neoplastic initiation and progression; these
data suggest MMPs as good targets for tumor biomar-
ker discovery. In humans, there are 24 MMP genes,
but only 23 MMP proteins [16], including 17 soluble,
secreted enzymes and 6 membrane-associated protei-
nases. MMPs are built up by a diverse structural
domain architecture, and differ in their substrate speci-
ficity and in temporal and tissue specific expression
patterns. MMPs were originally named for their pre-
ferred substrates within the extracellular matrix
(ECM): collagen-cleaving MMPs (MMP-1, -8, and -13)
were designated collagenases, gelatin (denatured col-
lagen)-cleaving MMPs (MMP-2 and -9) were termed
gelatinases, and MMPs degrading a broad spectrum of
ECM proteins were called stromelysins (MMP-3, -10,
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grew with the discovery of additional paralogs, includ-
ing the membrane-associated MMPs, a numbering sys-
tem was adopted, and MMPs are now grouped
according to their domain structure (Figure 1).
Many studies have characterized the increased expres-
sion of MMPs at both protein and mRNA levels, identi-
fying them as a key event leading to the initiation/
progression of BC and linking them with the ability of
cancer to metastasize. Thus, MMPs could be used as
tumor biomarkers and indicators of cancer metastasis
with diagnostic and prognostic usefulness [17,18]. On
the other hand, recent evidence underlines the fact that
some MMPs (such as MMP-8, also named collagenase-2
or neutrophil collagenase) may favor host defense
instead of stimulating tumor proliferation, suggesting
that these proteinases have an unexpected protective
biological role in cancer processes [19,20].
Among the MMP members involved in BC, both the
biochemical and molecular expression profile of MMP-1
(named also collagenase-1 or interstitial collagenase)
have been extensively analyzed in human BC. Although
there are a great number of valuable in vitro and in vivo
studies concerning its role in breast carcinogenesis (see
reviews [21-23]), some parts of its regulation and
expression (as an assisting marker in metastatic BC
diagnosis) remain poorly understood and a matter of
debate [21,24,25].
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Figure 1 Domain structures of secreted and membrane-anchored MMPs. The basic organizations of human MMP family members are
depicted: S, signal peptide; Pro, pro-peptide; Cat, catalytic domain, containing cysteine group (C);Zn, zinc ion; Fn, fibronectin-II- like repeats; Hpx,
hemopexin like domain; TM, transmembrane domain; GPI, glycol-phosphatidylinositol membrane anchor; C, cytoplasm tail; CA, cysteine array; Ig,
immunoglobulin-like domain; the flexible linker or hinge region is represented by a wavy black ribbon. The domain structure includes the signal
peptide, which guides the enzyme into the endoplasmic reticulum during synthesis, the propeptide domain, which sustains the latency of
MMPs, the catalytic domain, which houses the Zn2+ region and is responsible for enzyme activity, the hemopexin domain, which determines
the substrate specificity, and a small hinge region. Additional transmembrane and intracellular domains are also present: the hinge region in
MMP-9 is heavily O-glycosylated; the furin-activated MMPs and all of the membrane-anchored MMPs have a basic motif at the C-terminal end of
their prodomains;; the two gelatinases (MMP-2 and -9) contain three fibronectin-II-like repeats; four of the six MT-MMPs are anchored to the cell
membranes through a type I transmembrane domain and the other two through a glycosylphosphatidylinositol moiety. The membrane-
anchored MMP-23, has an N-terminal type II transmembrane domain. The two minimal domain MMPs and MMP-23 lack the HPX domain and, in
the latter enzyme, this domain is replaced by a C-terminal cystein array (Ca) and an immunoglobulin-like (Ig) domain. MMPs are produced in a
latent form and most are activated by extracellular proteolytic cleavage of the propeptide and finely regulated by the tissue inhibitors of
metalloproteinases (TIMP)[9].
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BMC Cancer [26] has retrospectively examined MMP-1
expression in both breast cancer cells and cancer-asso-
ciated stromal cells from BC patient to evaluate the rela-
tionship among MMP-1 and classic prognostic factors,
analyzing the extensively long follow-up time for cancer
specific survival in different BC subtypes.
Discussion
The highly complex BC tissue is composed of neoplastic
cells and stromal cell compartments [27], containing a
variety of mesenchymal cells (notably fibroblasts,
myofibroblasts, endothelial cells and inflammatory cells
associated with the immune system) (Figure 2). The spe-
cific contributions of the cancer-associated fibroblasts to
tumor growth are poorly understood, but it has been
suggested that they are able to promote the growth of
mammary carcinoma cells and to enhance tumor angio-
genesis [28-30], as well as through the secretion of pro-
teinases (including MMP-1) and other proteins (for
example, stromal-cell derived factor 1 (also called CXCL
12), syndecan-1, CXCR4 and Caveolin-1) [31,32]. The
molecular profile of the lethal breast cancer microenvir-
onment is based on activated cancer-associated
Figure 2 Schematic view of the role and functions of MMP-1 in breast cancer microenvironment. The breast microenvironment is
composed of ductal and luminal epithelial cells sitting on a layer of myoepithelial cells, and stromal cells (including leukocytes, fibroblasts, and
endothelial cells). The microenvironment alterations during breast cancer (BC) progression lead to a decrease of myoepithelial cells,
phenotypically altered because of signals coming from the tumor and stromal cells. The cell-cell and cell-matrix interactions during BC initiation/
progression involve the interplay among cancer-associated fibroblasts, macrophages and BC cells. The secretion of MMP-1 and the release of
soluble proteins (including EGF, VEGF, CD147, syndecan-1) in the breast milieuare able to activate tumor pathways, generating the ‘lethal BC
microenvironment’, which triggers a ‘vicious cycle’ between tumor and stromal cells, enhancing the BC growth, and promoting the invasive and
metastatic processes via paracrine interactions [13]. The unexpected roles of MMP-1 interstitial collagenase are related to the proteolytic activity
in the ECM compartment and the cell-cell interactions. The unexpected nuclear localization of some MMPs has been recently linked to new
functional roles of these proteases within nuclei of tumor cells, with the ability to cleave peculiar nuclear peptides (Mannello et al, ms in
preparation). The proteolytic activity of MMP-1 in BC cells is linked to the cleavage/release of soluble VEGF, EGF, CXCL 12 and CD147 from their
receptor complexes. These proteins are able to activate crucial cancer metabolic routes (like HIF-1-dependent and MAPK and ERK-dependent
pathways) that promote BC proliferation, triggering a vicious cycle through the molecular activation of some transcription factors (like AP-1, PEA3
and Ets), indispensable switches for the HER-2, CXCR4 and MMP-1 gene regulation [39]. The secretion of MMP-1 is also able to activate other
MMPs (like MMP-2 and -9) which have been widely recognized as crucial steps for the BC evolution [14].
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collagenase MMP-1 (both at protein and mRNA levels),
which facilitate angiogenesis and increase ECM degrada-
tion, both crucial processes for the invasive and migra-
tory phenotype of metastatic BC [14]. Interestingly, it
has also been demonstrated that human epidermal
growth factor receptor 2 (HER-2) induces MMP-1
expression through the enhanced regulation of the tran-
scription factor/proto-oncoprotein Ets-1, suggesting that
( c o n t r a r yt ot h ep r o t e c t i v er o l eo fM M P - 8n e u t r o p h i l
collagenase [20]) the interstitial collagenase MMP-1 may
significantly affect the metastatic behavior of BC cells
[33]. The same biochemical behaviors and biological
functions of both MMP-1 and -8 collagenases have also
been detected in plasma samples collected from BC
patients with poor prognosis [34].
The recent study of Boström and Colleagues [26] is
helpful in that it sought to link the expression of MMP-
1 with a broader picture of immunohistochemical bio-
marker changes, and their relationships between BC and
stromal cells. According to the well-established role of
MMP-1 in BC promotion and outcome [21,35], the
authors claim that the independent prognostic value of
MMP-1 is mainly based on the positive correlations
with tumor grade and p53 positivity in tumor and stro-
mal cells; the peculiar expression of MMP-1 in stromal
cells also showed a significant association of BC with
HER-2 over-expression and triple negative BC. Further-
more, in the luminal B BC subtype (estrogen receptor
and/or progesterone receptor positive, other than HER-
2 positive), MMP-1 expression in stromal cells was
higher than in the luminal A subtype (estrogen receptor
and/or progesterone receptor positive, and HER-2 nega-
tive). Also, the luminal B subtype stromal cells showed
higher MMP-1 expression when compared to triple
negative BC cells (identified as a basal-like subtype in
about 70% of cases). From the more than 20 years survi-
val analyses, Boström and colleagues revealed that there
were statistically significant differences in BC-specific
survival among women with tumors with high versus
low expression of MMP-1, tumor grade I versus III, tri-
ple-negative versus non-triple negative, basal-like versus
non-basal-like tumors, and low versus high Bcl-2 and
Ki-67 expressions. All these data reveal that high MMP-
1 positivity in both stromal and tumor cells was signifi-
cantly associated with tumor evolution, poor prognosis
and shortened survival. Noteworthy also is the higher
MMP-1 expression in both the cytoplasm and nuclei of
BC cells with respect to stromal cells, adding new infor-
mation to the poorly characterized and unexpected role
of nuclear MMPs (Mannello et al, unpublished observa-
tions), suggesting them not just for ECM anymore [11].
In this respect, it has recently been suggested that some
MMPs (such as the MMP-3 stromelysin and MMP-2
gelatinase) may be involved in transcriptional gene regu-
lation [36] and the cleavage of poly-ADP-ribose-poly-
merase [37].
Recent studies highlight the biological importance of
stroma in breast physiopathology [38], suggesting that
the gene expression and regulation of some MMPs are
largely restricted to the stromal compartment [39].
Although the role of the stromal compartment in BC
had been originally depicted as the Cinderella of the
cancer biology, even more evidence has supported the
crucial role of stromal cells in tumor evolution and then
in BC patient survival. Early studies showed that the
normal mammary microenvironment is capable of
reverting the malignant phenotype of BC cells by indu-
cing a more differentiated state, suggesting that cancer
c e l l sm a yo n l yt h r i v ei na na b n o r m a le n v i r o n m e n ti n
which they evolved [40]. Pathologists have also long
noted the prognostic value of certain histopathological
features of BC (including lymphocytic infiltration and
angiogenesis), suggesting a role for non-epithelial cells
in carcinogenesis, as shown by differences in tumor
initiation and progression depending on the variability
in germline genotypes and phenotypes [41].
Despite the convincing observations implicating a role
for microenvironmental and systemic alterations in
breast tumorigenesis (reviewed in [42]), our understand-
ing of the genes and metabolic pathways mediating cel-
lular interactions and paracrine regulatory networks
among various cell types in both normal and neoplastic
breast tissue is still limited. However, it has been clearly
demonstrated that gene expression changes occur in all
cell types during breast tumor progression, but clonally
selected genetic alterations are restricted to tumor
epithelial cells [43]. Interestingly, the comparison of
myoepithelial cells from normal breast tissue with ductal
carcinoma in situ (DCIS) yielded the highest number of
consistently differentially expressed genes; a significant
fraction of these encoded for secreted proteins and cell
surface receptors, suggesting intensive autocrine/para-
crine regulatory loops in the breast pre-cancer and can-
cer microenvironment [27,30,31,42].
It has recently been demonstrated that the gene
expression signature of epithelial cells correlated with
tumor grade but not with histologic stage, whereas
genes up-regulated in tumor-associated stroma included
many ECM-related molecules (including MMP-1 col-
lagenase), expressed at higher levels in invasive com-
pared with in situ tumors [44,45]. In particular, it has
been recognized that, among the mesenchymal cells
constituting the stroma, both the cancer-associated
fibroblasts and the inflammatory cells associated with
the immune system are able to drive cancer initiation
and progression through peculiar biochemical pathways
and molecular signatures, significantly different between
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gene expression patterns, but the lack of clonally
selected somatic genetic alterations in the tumor-asso-
ciated myoepithelial and stromal cells, has also sug-
gested potential epigenetic alterations; this may be
because stromal cells isolated from normal and tumor
tissues are known to maintain their differences even
after prolonged cell culture and in xenograft studies (as
reviewed in [38]).
The historically prevailing view of BC progression is
focused on tumor epithelial cells, whereby gradual pro-
gression of a tumor through defined steps is entirely
due to the accumulation of both genetic and epigenetic
alterations that confer progressively malignant pheno-
types [47]. However, this model has been challenged
after multiple studies demonstrating the importance of
the microenvironment in shaping tumor evolution and
progression through the new functions of several MMPs
(including MMP-1 collagenase)[42,47-50].
With this background, the molecular and biochemical
profiling of a lethal BC microenvironment has led to the
identification of new functions of MMP-1 in the stromal
microenvironment of BC, revealing a significant link
between cancer-associated fibroblasts and MMP-1
expression with metastatic tumor progression and/or
poor clinical outcome [21]. In particular, the paper of
Boström and colleagues [26] sheds further light on these
relationships, demonstrating significant differences of
MMP-1 expression by cancer-associated stromal cells in
luminal A, luminal B and triple-negative BC subclasses.
The importance of MMP-1 expression and its cellular
localization (other than the unexpected presence of
nuclear MMP-1) in BC stromal cells is in agreement
with the functional and clinical relevance of microenvir-
onmental alterations in breast tumorigenesis. Their
results support the molecular evidence that high MMP-
1 mRNA expression and both aplotypes and polymorph-
isms of MMP-1 promoter gene may represent a risk fac-
tor in patients with invasive BC [51], and recognize
M M P - 1a sap r o g n o s t i cm a r k e ri np a t i e n t sw i t hi n v a -
sive/metastatic BC [52-54]. Thus, Boström’s study pro-
vides stronger evidence that the expression of MMP-1
in stromal fibroblasts of BC help to identify patients
with atypical tumor-stromal fibroblasts in which MMP-
1 may contribute to BC invasiveness and metastatic
behavior.
Conclusions
Boström and colleagues provide us with a stronger
scientific basis for understanding the involvement and
cooperation of both tumor and stromal cells in BC pro-
gression and outcome, as well as the role of MMP-1
expression (both in cytoplasm and nuclei) for metastatic
dissemination, identifying BC women with shortened
relapse-free survival and poor outcome.
Although we are now learning that the useful relation-
ship among MMP-1 expression and well-known clinic/
pathologic-prognostic factors (such as Ki-67, HER-2,
Bcl-2, tumor grade and cancer subtypes) may help us to
enhance and increase the clinically useful prognostic
factors, what we need are future biochemical, molecular
and clinical studies assessing many different biomarkers
head-to-head, because MMP-1 analysis alone is no
longer the way to go.
In this respect, the perspectives should involve studies
focused on gene and protein expression profiling of
stromal alterations associated with BC progression, iden-
tifying key transcriptional changes that occur early in
cancer initiation/development. For example, a possible
synopsis for future research could include:
1 .T h ep r o f i l eo ft h eM M Ps u p e r f a m i l y( i n c l u d i n gt h e
proteomic analysis of both protective and dangerous
MMPs). This research will evaluate the kind of MMP
which is involved in the proteolytic cascade cleaving/
regulating not only structural components of both ECM
and nuclear compartments, but also the modulation of
several growth factor precursors, cell surface receptors,
cytokines and cell adhesion molecules; on the other
hand, we should obtain information about the MMPs
involved in tumor-suppression [20].
2. The analysis of tissue inhibitors of metalloprotei-
nase (TIMPs) (well-known inhibitors of MMPs also
characterized by MMP-independent functions in cancer
biology [9,55]). This approach allows the analysis of the
proteolytic/antiproteolytic balance, as a cancer/meta-
static specific switch). It will be interesting for future
studies to identify processes that control the earlier
stages of disease progression, helping to decipher the
molecular and biochemical mechanisms underlying cel-
lular and microenvironmental interactions in the breast
tumors.
3. The screening of both MMP gene aplotypes and
polymorphisms, to obtain a phamacogenomic profile of
the individual variation in drug response and therapeutic
efficacy [56]. Considering the potential contribution of
BC stromal microenvironmental alterations on MMP-1
biochemical and molecular alterations, the knowledge of
MMP gene aplotypes and/or polymorphisms may help
in the design of more efficient target therapy, limiting
drug-resistance and underlining the importance of anti-
target identification in drug development for blocking
metastases [14].
4. The histochemical and molecular analysis of the
nuclear localization of MMP-1 protein (in latent and/or
active form) to evaluate its role during cancer associated
apoptosis and possible therapeutic potential (Mannello
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preparation).
As highlighted by Boström and colleagues, MMP-1
expression in both stromal and tumor cells may control
BC progression, suggesting that BC metastasis and out-
come are driven by complex and reciprocal interactions
between epithelial cancer cells and their stromal micro-
environment. The biochemical and molecular profiling
of invasive BC will be crucial to identify a ‘lethal tumor
microenvironment’ [57] associated with metastatic
tumor progression and/or poor clinical outcome for the
leading cause of cancer death among women in high-
income countries [1]. It is noteworthy that the ‘lethal
tumor microenvironment’ is likely to have an impact on
numerous solid tumors in different parts of the body,
widening the impact of the results of Boström and col-
leagues to other fields of oncology (such as in breast,
lung, pancreas and haematological malignancies)[50,58].
In fact, the tumor microenvironment alterations in
human cancer not only influence tumor progression and
predict prognosis, but also have major effects on the
efficacy of cancer therapy, especially the targeted therapy
aimed at growth factor receptors and secreted proteins,
such as HER-2 and MMP-1. Modifications in the cancer
microenvironment may alter the fitness landscape pro-
viding a possible growth advantage for cells with tumor-
initiating genetic-epigenetic changes [59,60].
Ultimately, the study of Boström and Colleagues
opens new possibilities and the ability to specifically tar-
get the expression of MMP-1, a particular MMP
involved in BC initiation/progression, aberrantly
expressed in the metastatic process, suggesting further
diagnostic, prognostic and therapeutic potential.
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